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Mass vaccination, immunity and 
coverage: modelling population 
protection against foot-and-mouth 
disease in Turkish cattle
T. J. D. Knight-Jones1,2, S. Gubbins1, A. N. Bulut3, K. D. C. Stärk2, D. U. Pfeiffer2, 
K. J. Sumption4 & D. J. Paton1
Foot-and-mouth disease (FMD) in Turkey is controlled using biannual mass vaccination of cattle. 
However, vaccine protection is undermined by population turnover and declining immunity. A dynamic 
model of the Turkish cattle population was created. Assuming biannual mass vaccination with a single-
dose primary course, vaccine history was calculated for the simulated population (number of doses 
and time since last vaccination). This was used to estimate population immunity. Six months after the 
last round of vaccination almost half the cattle aged <24 months remain unvaccinated. Only 50% of 
all cattle would have received >1 vaccine dose in their life with the last dose given ≤6 months ago. 
Five months after the last round of vaccination two-thirds of cattle would have low antibody titres 
(<70% protection threshold). Giving a two-dose primary vaccination course reduces the proportion of 
6–12 month old cattle with low titres by 20–30%. Biannual mass vaccination of cattle leaves significant 
immunity gaps and over-reliance on vaccine protection should be avoided. Using more effective 
vaccines and vaccination strategies will increase population immunity, however, the extent to which 
FMD can be controlled by vaccination alone without effective biosecurity remains uncertain.
Vaccines play a crucial role in the control of foot-and-mouth disease (FMD) and are widely used throughout the 
world1. Whilst FMD has been eradicated in Turkish Thrace, mass vaccination has failed to control the disease in 
the rest of the country (Anatolia, Fig. 1). FMD vaccination in Turkey typically consists of biannual mass vacci-
nation of cattle. Most farms in Anatolia are smallholdings dependent upon communal grazing, and vaccination 
should be performed before animals are turned out for spring grazing and at the end of the grazing season in 
autumn, with cattle typically housed over winter.
Within Turkey, there is great variation in topography, climate and livestock husbandry. This results in differ-
ences in the seasonality of livestock births and population age structure. These demographic factors determine 
the proportion of cattle eligible for routine FMD vaccination (≥ 2 months old), the proportion recently vac-
cinated and the proportion that have received multiple doses. These proportions change with time as animals 
are born, age and die. However, population structure is rarely considered in detail during livestock vaccination 
programmes2.
The trivalent vaccine used in Turkey at the time of the study was reported to be ≥ 3PD50, covering serotypes 
O, A and Asia-1. The 50% protective dose (PD5o) is a measure of vaccine potency assessed in a challenge study. A 
single dose of a ≥ 3PD50 vaccine contains at least three times the dose required to prevent clinical FMD in 50% of 
cattle that have FMD virus injected into the tongue three weeks after vaccination.
Quality FMD vaccines can induce immunity lasting for ≥ 6 months after a single dose. Immunity is broader 
and longer-lasting with a faster onset if vaccine potency is high3–6. However, many FMD control programmes 
use vaccines with a shorter duration of immunity and several doses of vaccine are required before protection is 
sustained7–9. When first vaccinated, cattle should receive two doses of vaccine approximately one month apart 
(a two-dose primary course)5,7,10. However, to save resources, a single-dose primary course is used in many coun-
tries, including Turkey at the time of this study.
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We previously assessed immune response in Turkish cattle after routine FMD vaccination under field con-
ditions8. However, that study only assessed a small subgroup of the vaccinated population and did not take into 
account age structure of the population at large and population turnover. In addition, the vaccine history of those 
sampled did not reflect that of the population at large.
The objective of this modelling study was to quantify population immunity resulting from mass vaccination 
of cattle in Turkish Anatolia, using data from 2012/13. As we wished to evaluate protection provided by the vac-
cination programme, immunity from natural infection was not considered. Percentage vaccinated and vaccine 
immunity were modelled over the annual production cycle. The effect and cost-effectiveness of a single versus a 
two-dose primary course were estimated.
Materials and Methods
Referenced field studies obtained ethics approval from the University of London and The Pirbright Institute. 
Methods were carried out in accordance with approved guidelines.
We developed a simulation model of FMD population immunity in Turkish cattle. This was undertaken by 
combining a dynamic model of population structure and vaccine coverage with estimates of post-vaccination 
immune response8. Two main sources of data were used to inform the model: (a) demographic data from nation-
wide cattle surveys, and (b) an extensive field study of post-vaccination serology8.
Maternally derived immunity and immunity from infection have not been considered. The study assessed 
Anatolia and not FMD-free Turkish Thrace where different vaccines are used (Fig. 1).
Cattle population model. The population model was designed to represent cattle age structure in each 
province. The number of cattle < 12 months, 12 to < 24 months and ≥ 24 months on 31st December 2012 was 
obtained for each sex in each province from government census records11. Demographic data taken from sepa-
rate randomised cross-sectional surveys of cattle, conducted in 2009, 2010 and 2012, covering all provinces, were 
used to estimate month of birth within age categories. The FMD sero-surveys sampled 96 249 cattle aged 6–24 
months12. For each of the 78 provinces in Anatolia, survey data from cattle 6–17 months old were used to create 
a distribution of month of birth (Supplementary Dataset, month_of_birth_2.xls). Each distribution was then 
sampled n times, where n was 1% of the number of cattle within each age category for each province. This gave a 
simulated population of 135 453 cattle representing a random selection from across Anatolian Turkey.
Having sampled the month of birth for the simulated population, the actual day of birth was selected at ran-
dom from a uniform distribution (e.g. from 1–31 for January). As the age distribution of cattle ≥ 24 months old 
was not available, those cattle ≥ 24 months old were assumed to be equally distributed between the ages of two 
and five years old.
The simulated population reflected the age-sex structure for each province on 31st December 2012.
Vaccine coverage. Once the cattle population was simulated, the vaccination history of each animal was 
derived assuming nationwide biannual mass vaccination since 2007 on the 25th March and 25th September each 
year (the 2012 average date of autumn vaccination). If a simulated animal was ≥ 2 months old on a vaccination 
date it was eligible for vaccination.
To incorporate realistic levels of vaccine coverage (the proportion of eligible cattle vaccinated), district cov-
erage was assumed to vary (Anatolia, Turkey has 904 districts in 78 provinces). For each district in the simulated 
population, the proportion of eligible cattle typically vaccinated at mass vaccination (vc) was sampled from a 
betapert distribution (minimum = 40%, maximum = 100%, most likely = 80%), based on Turkish field studies13. 
Whether or not an eligible animal was actually vaccinated, during a particular round of vaccination, was then 
determined by a Bernoulli distribution, with probability of vaccination vc.
Figure 1. Map of Turkey. The locations of the 23 villages included in the prospective serological field survey 
used to inform the model in this study are marked with crosses8. The hashed lines show the FMD-free with 
vaccination zone of Thrace. Turkey consists of seven regions, divided into 81 provinces and 957 districts, 
containing about 48,000 villages. Created using ArcGIS® software by Esri (ArcMAP10.3).
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Population immunity. SP prediction models. Antibody levels against FMD virus structural proteins (SP) 
are a strong correlate of protection and can be measured to assess FMD immunity14–18. Log10 SP antibody titres 
for serotypes A, O and Asia-1 were predicted for each animal in the simulated population. SP titre measured 
by liquid phase blocking ELISA (LPBE) was predicted in two steps using regression models fitted to data from 
an extensive post-vaccination field study performed in Turkey8. Predictor variables were 1) number of vaccine 
doses received in a lifetime (which was correlated with age), 2) time since last vaccination and 3) was a single or 
two-dose primary course given8.
Firstly, a GEE (generalised estimator equation) logistic regression model predicted the probability of an ani-
mal having a titre equal to or higher than 1:32, which was the lowest dilution tested. This probability was then 
used as the parameter in a Bernoulli distribution.
In the second step, for each animal predicted to have a titre above the detection threshold (≥ 1:32), an interval 
regression model was used to determine expected Log10 (SP titre). For these cattle, final predicted SP titre was 
determined by drawing a sample from a normal distribution centred on this expected titre, with standard devia-
tion equal to the model residual standard deviation19.
Available data only described the effect of the two-dose primary course on immunity following initial vacci-
nation. Data showing its effect on immunity after further six-monthly rounds of vaccination were not available8. 
Therefore, the regression coefficient for the two-dose primary course was only applied to simulated cattle at first 
vaccination. After further rounds of vaccination the two-dose primary course was modelled as the effect of having 
received an extra dose of vaccine in an animal’s lifetime.
Almost all adult cattle > 24 months would have been vaccinated ≥ 3 times. As cattle vaccinated ≥ 3 times are 
usually able to sustain antibody titres throughout the duration of the six month inter-vaccination interval they 
were combined in one group8. Unvaccinated cattle were assigned a titre of zero.
Modelling uncertainty. To account for variability and uncertainty, Monte Carlo simulation was used. The pop-
ulation model was simulated 1000 times. For each iteration, the regression parameters used for prediction were 
sampled from normal distributions with mean equal to the regression coefficient and standard deviation equal to 
the robust standard error. SP titres were then predicted for each iteration and summary statistics were produced, 
including the proportion of the simulated population with a titre < 1:102. In challenge studies animals with a 
titre ≥ 1:102 are likely to be protected against homologous challenge (personal communication A.N. Bulut), with 
approximately 70% protected20–22.
To assess the accuracy of SP predictions, titres were predicted for the cattle in the field study used to fit the 
regression models8. These predicted titres were then compared with actual titres for the same animals. Analysis 
was performed using R23. In the results, median predicted values are shown with 95% prediction intervals (PI), 
i.e. 2.5th to 97.5th percentiles.
Coverage and immunity over time. The population model was used to assess vaccination and immune 
status on 25th October 2012 (one month post-vaccination, when antibodies peak) and 14th February 2013 (the 
maximum time after vaccination that antibody titre was assessed in the post-vaccination field study used to fit 
the prediction models8). Vaccination and immune status were also assessed on the date of autumn and spring 
vaccination, (25th September 2012 and 25th March 2013). However, as the time since last vaccination on these 
dates is greater than in the data used to fit the regression models, caution is required when assessing antibody 
levels on these dates.
Assessment of the relationship between percentage vaccinated and population immunity is presented in the 
Supplementary Methods and Results.
Vaccine homologous antibody. Antibodies in post-vaccination sera bind vaccine homologous virus bet-
ter than they bind other strains of FMD virus. The vaccine in the field study used to fit prediction models was the 
trivalent FMD vaccine produced by the Sap Institute in Ankara, Turkey, containing FMD strains O Panasia II [O 
Tur 07], A Iran 05 [A TUR 06] and Asia-1 Sindh-08 [Asia-1 TUR 11]. The antigens used in the LPBE (O Manisa, 
A22 IRQ 24/64 and Asia-1 Shamir) are all different to the antigens used in the vaccine8. Therefore, virus neutral-
isation (VN) tests were used to estimate the effect of this antigen mismatch on predicted protection as described 
by Knight-Jones et al. (2015).
The proportion protected was then adjusted according to the difference in the proportion above the 70% 
protection threshold according to VN and LPBE tests. This was done separately for simulated LPBE titres below 
the detection threshold, detectable but < 1:102 and finally those ≥ 1:102. Adjustments were made using Betapert 
distributions based on the median, 2.5th and 97.5th percentiles shown in Table 2 of Knight-Jones et al. (2015), 
which represent the proportion above the homologous VN 70% protection threshold according to LPBE titre.
Cost-effectiveness of the two-dose primary course. The additional cost of routinely using the 
two-dose primary course was estimated by multiplying the number of cattle vaccinated for the first time at spring 
and autumn by the estimated cost of vaccination (vaccine plus administration) taken as Betapert (min = US$0.4, 
max = US$3, most likely = US$1), based on costs in Turkey and elsewhere1,24–26. The cost-effectiveness of the 
strategy was estimated as the increase in the percentage of cattle with a titre above the 70% protection threshold 
for each additional US$100,000 in vaccination costs. This was assessed after adjustment to reflect protection 
against homologous challenge assessed by VN for serotype O only.
Calculations for the two-dose primary course included administering the two-dose primary course to all cattle 
when first vaccinated, including those that were not presented for vaccination as calves.
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Results
Population structure. The proportion of births occurring in a particular month varied by region (Fig. 2). 
Age distribution details are shown in Table 1 and Supplementary Table S1, and Fig. S1.
Vaccine coverage. When incomplete coverage of eligible cattle was incorporated, about 20% of cattle were 
unvaccinated six months after the last round of vaccination. An additional 15% of cattle, although vaccinated, had 
not been vaccinated for a year or more. Only about half of all cattle would have been vaccinated ≥ 3 times since 
birth (Table 1). Looking at cattle < 12 months old, about 82% had not previously been vaccinated at the time of 
autumn vaccination, with about 69% unvaccinated at the time of spring vaccination, the difference resulting from 
more calves being born in spring/summer than in autumn/winter. For all cattle aged < 24 months, 44% would be 
unvaccinated at the time of autumn vaccination.
Even if all of the 94.7% of cattle ≥ 2 months old were vaccinated in spring 2012, then six months later, new 
births would have increased the percentage of unvaccinated cattle to 18.5% (Table 1 and Fig. S2).
Post-vaccination SP titre. The coefficients for the regression models used to predict SP titre are shown in 
Table 2. Titre increases with prior vaccination and a two-dose primary course, declining with time since vaccina-
tion. Figure 3 shows that the two-step modelling process accurately recreated the original antibody distribution. 
As right and interval censoring, present in the original serial dilution data, were removed in the predicted titres, 
the latter were slightly raised without truncation at the maximum test dilution.
Population antibody levels were highly bi-modal (Fig. 3 and Supplementary Fig. S3). Many cattle were below 
the antibody detection threshold of 1:32, the rest had SP titres that varied around an average of roughly 1:102.
Only at peak antibody response, one month after the last round of vaccination, did more than half the simu-
lated cattle population have a titre ≥ 1:102 (Table 3). A quarter had no detectable antibodies at this time of peak 
response. Antibody levels were lower for serotype A and largely similar for O and Asia-1. Low serotype A titres 
were partly a result of differences in vaccine and LPBE antigen (see VN adjustments later).
By February, one month before re-vaccination, 68% (95% PI: 60–75%) of cattle had a serotype O SP titre of 
below 1:102. Using a two-dose primary course resulted in only an additional 8% having a titre above this thresh-
old. However, the beneficial effect occurred mainly in young animals. By mid-February, with a single-dose pri-
mary course, roughly 80% of 6-< 12 month old cattle had titre < 1: 102 compared to 50–60% with the two-dose 
primary course (all serotypes). An additional 20–30% were also lifted above the detection threshold (1:32).
Vaccine homologous antibody. Compared to LPBE estimates, protection against vaccine homologous 
virus was higher when predicted by VN except for Asia-1. After adjusting LPBE protection estimates to reflect 
protection against vaccine homologous virus predicted by VN, assessed on 25th October 2012 (one month 
post-vaccination), 26% [95% PI: 19–34%], 37% [95% PI: 28–48%] and 59% [95% PI: 46–72%] of cattle were 
expected to be below the 70% protection threshold for serotypes O, A and Asia-1 respectively. The same statistic 
assessed in mid-February would yield 44% [95% PI: 33–56%], 48% [95% PI: 38–60%] and 74% [95% PI: 60–83%] 
below the threshold with a single-dose primary course and 39% [95% PI: 29–51%], 44% [95% PI: 34–56%] and 
71% [95% PI: 58–81%] if a two-dose primary course were used, again for serotypes O, A and Asia-1, respectively.
Cost-effectiveness of the two dose primary course. Looking at serotype O only, after autumn vac-
cination, by mid-February, the two-dose primary course increased the proportion above the 70% protection 
threshold, adjusted to represent homologous challenge using VN, from 56% [95% PI: 44–67%] to 61% [95% PI: 
49–71%]. The total cost of administering an additional vaccine dose to the 1.9 million cattle first vaccinated in 
Figure 2. Relative frequency of births over the year for cattle from different regions of Turkey. Taken 
from month of birth of cattle included in three Anatolian FMD random sero-prevalence surveys (2009, 2010 
and 2012), n = 96 249. Coastal regions, except for the mountainous Black Sea region, experience less seasonal 
temperature variation and had more uniform birth rates throughout the year. Spring/summer calving is 
common in Central and Eastern Anatolia, where winter temperatures often average below 0 °C.
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autumn 2012 would be US$2.3million [95% PI: US$ 2.3 to 2.4million]. This equates to an extra 0.2% [95% PI: 
0–0.8%] above the 70% protection threshold per US$100,000 of additional vaccination costs.
Routine use of the two-dose primary course increased the proportion of cattle aged 6-< 18 months old with 
predicted titres above the 70% protection threshold from 51% [95% PI: 39–63%] to 66% [95% PI: 58–74%]. This 
equated to an additional 0.7% [95% PI: 0.1–1.3%] of this age group above the threshold for every additional 
US$100,000 spent.
Discussion
Key findings. In this study, we extended the serological approach to FMD post-vaccine monitoring, by incor-
porating estimates of immune response into a dynamic, demographic model of vaccine coverage. The model 
predicted that the FMD vaccination programme in Anatolia provided only limited protection against FMD. 
Although the vaccination programme uses biannual mass vaccination of cattle, five months after the last round of 
vaccination, half to two-thirds of cattle would have low antibody titres.
Declining antibodies and the need for multiple doses. Time since last vaccination and the number of animals that 
had received three or more vaccinations in their life had a large effect on predicted immunity. With six-monthly 
vaccination and a single-dose primary course, sustained protection could not be achieved at a young age due to 
rapidly declining antibodies and the need for multiple doses. Vaccines that induce sustained immunity after one 
or two doses are required. The vaccines assessed in this study are reported to be ≥ 3PD50. Although few data are 
available, following a single dose with a ≥ 6PD50 vaccine, antibody levels have been observed to remain high for 
six months or more7,27. Under this scenario protection levels would mirror the proportion vaccinated with mini-
mal decline in immunity for the next six months or more. Higher potency vaccines are also more likely to protect 
in the event of poor vaccine match6.
Two-dose primary course. Considering cattle < 12 months old, five months after the last round of vaccination 
about 80% would have low titres. Using a two-dose primary vaccination course improved immunity in young 
animals to levels similar to adults; it also provides an additional opportunity to vaccinate young-stock previously 
Number of doses 0 1 2 ≥3 Total
Evaluated 25th 
Sept 2012†
Months since last 
vaccination
Unvaccinated 22% [21.9–22.2] 0% 0% 0% 22% [21.9–22.2%]
6 0% 10.4% [10.4–10.5] 13.1% [13.1–13.15] 39.4% [39.2–39.6] 62.9% [62.7–63.1]
12 0% 3.19% [3.18–3.2] 1.87% [1.8–1.9] 6.7% [6.6–6.8] 11.8% [11.6–11.9]
≥ 18 0% 0.77% [0.75–0.79] 0.7% [0.7–0.7] 1.85% [1.7–1.9] 3.3% [3.1–3.4]
Age [months]
< 6 13.1% [12.9–13.2] 0% 0% 0% 13.1% [12.9–13.2]
6 -< 12 6.8% [6.7–6.9] 4.4% [4.3–4.5] 0% 0% 11.2% [11.1–11.4]
12 -< 18 1.5% [1.4–1.6] 6.1% [6–6.3] 6.1% [6–6.2] 0% 13.7% [13.6–13.9]
18 -< 24 0.5% [0.5–0.6] 2.8% [2.7–2.9] 6% [5.9–6.1] 3% [2.9–3.1] 12.3% [12.2–12.5]
≥ 24 0.1% [0.1–0.2] 1% [0.9–1.1] 3.5% [3.4–3.6] 44.9% [44.8–45] 49.6%*
Total 22% [21.9–22.2] 14.5% [14.4–14.6] 15.6% [15.5–15.7] 47.9% [47.8–48.1] 100%
If all eligible cattle always vaccinated 18.5% [18.4–18.6] 81.5% [81.4–81.6] 72.1% [72–72.2] 55.9% [55.7–56] Eligible that day 96.6% [96.5–96.65]
Evaluated 25th 
March 2013‡
Months since last 
vaccination
Unvaccinated 20% [19.8–20.2] 0% 0% 0% 20% [19.8–20.2]
6 0% 14.4% [14.2–14.6] 10.3% [10.2–10.5] 41.3% [41.1–41.5] 66% [65.8–66.3]
12 0% 2.4% [2.3–2.4] 2.4% [2.3–2.4] 6.7% [6.5–6.7] 11.4% [11.2–11.6]
≥ 18 0% 0.7% [0.7–0.8] 0.4% [0.4–0.45] 1.4% [1.4–1.5] 2.6% [2.5–2.7]
Age [months]
< 6 11.2% [11–11.3] 0% 0% 0% 11.2% [11–11.3]
6 -< 12 5.6% [5.5–5.7] 7.5% [7.4–7.7 0% 0% 13.2% [13–13.3]
12 -< 18 1.8% [1.7–1.8] 6.6% [6.5–6.7] 3.8% [3.7–3.9] 0% 12.1% [12–12.3]
18 -< 24 0.4% [0.4–0.5] 2.5% [2.5–2.6] 5.9% [5.8–6] 5% [4.9–5.1] 13.9% [13.8–14]
≥ 24 0.1% [0.1–0.2] 1.1% [1–1.1] 3.6% [3.5–3.7] 44.8% [44.7–44.9] 49.6*
Total 20% [19.8–20.2] 17.7% [17.5–17.9] 13.3% [13.2–13.5] 49.8% [49.7–50] 100%
If all eligible cattle always vaccinated 14.5% [14.4–14.6] 85.5% [85.4–85.6] 69.9% [69.8–70] 60% [59.8–60.1] Eligible that day 94.7% [94.6–94.8]
Table 1.  Median predicted proportion of cattle vaccinated during mass FMD vaccination in Turkey [with 
95% PI in brackets], allowing for incomplete coverage of eligible cattle assessed six months after the last 
round of vaccination**. Autumn revaccination (25th September 2012) would vaccinate 74.5% [95% PI: 74.3–
74.8%] of eligible cattle, spring revaccination (25th March 2013) would vaccinate 73.2% [95% PI: 73–73.4%] of 
eligible cattle. The median total does not necessarily equal the total of the subcategory medians. This, along with 
rounding, resulted in minor discrepancies with margin totals. *Fixed sampling proportion used from census 
data. **District level coverage was described by a Betapert distribution (minimum = 40%, maximum = 100%, 
most likely = 80%). †i.e. Assessed on day of autumn 2012 vaccination BEFORE vaccination performed. ‡i.e. 
Assessed on day of spring 2013 vaccination BEFORE vaccination performed.
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missed. Young cattle experience a high incidence of FMD13. Although the two-dose primary course requires sig-
nificant additional resources (about 20% more doses), reducing susceptibility of young-stock as soon as possible 
is vital.
Clusters of low coverage. Six months after the last round of vaccination about 20% of cattle would be unvacci-
nated with only around 50% vaccinated more than once in their life, with the last dose received ≤ 6 months ago. 
Two-thirds of cattle < 12 months old may remain unvaccinated when turned out to communal grazing at spring. 
This results from both a failure to vaccinate cattle that should be vaccinated and the presence of animals that at the 
previous round of vaccination were either too young for vaccination (< 2 months) or not yet born.
Regression model Parameter
Serotype O Serotype A Serotype Asia-1
Coefficient [95% CI] P Coefficient [95% CI] P Coefficient [95% CI] P
Step 1: (Logistic)  
Titre ≥ 1:32  
n = 1045
Intercept 
[vaccinated with 
single dose]
2.1 [1.8–2.5] < 0.001 0.6 [0.3–0.8] < 0.001 2.3 [1.9–2.7] < 0.001
Prior vaccination 
[effect per dose 
0-≥ 2]†
0.5 [0.09–0.9] 0.02 0.4 [0.1–0.7] 0.009 0.2 [− 0.2–0.6] 0.4
Time since last 
vaccination [effect 
per day]
− 0.01 [− 0.02 to −0.01] < 0.001 − 0.006 [− 0.009 to − 0.003] < 0.001 − 0.01 [− 0.02 to − 0.007] < 0.001
Two-dose primary 
course given 1.4 [0.8–2] < 0.001 1.2 [0.9–1.6] < 0.001 1.3 [0.7–1.8] < 0.001
Step 2: (Linear)  
Log10(SP titre)
Intercept 
[vaccinated with 
single dose]
2.25 [2.2–2.3] < 0.001 2.1 [2–2.2] < 0.001 2.3 [2.25–2.4] < 0.001
Prior vaccination 
[effect per dose 
0-≥ 2]†
0.06 [0.01–0.1] 0.02 0.05 [− 0.001–0.1] 0.08 0.06 [0.02–0.1] 0.007
Time since last 
vaccination [effect 
per day]*
− 0.001 [− 0.002 to −0.0006] < 0.001 − 0.0005 [− 0.001 to 0.0003] 0.2 − 0.002 [− 0.003 to − 0.001] < 0.001
Two-dose primary 
course given 0.2 [0.14–0.26] < 0.001 0.11 [0.06–0.17] < 0.001 0.17 [0.1–0.2] < 0.001
n [excludes cattle 
with titre < 1:32] 843 638 887
Table 2.  Regression coefficients from the two-step regression modelling process used to predict post-
vaccination SP titre of cattle fitted to data from a prospective field study in Turkey (October 2012–March 
2013)8. All unvaccinated cattle were given a zero titre. In step one, vaccinated cattle were assessed for their 
likelihood of having a detectable titre (≥ 1:32) using a GEE model with a logistic link function (log Odds Ratios 
are reported). In step two, the Log10(SP titre) was modelled in cattle with titres ≥ 1:32 using interval linear 
regression to allow for censoring in the data. 95% confidence intervals [95% CI] are reported calculated from 
robust standard errors, allowing for repeat sampling of individual cattle. Unvaccinated cattle were given a titre 
of zero. *An exponential decay function, as Log10(SP titre) is modelled. †Age was excluded as it was collinear 
with number of prior vaccine doses.
Figure 3. Violin plot showing actual SP titres after FMD vaccination (labelled “data”) and predicted SP 
titres for the same cattle (serotypes O, A, Asia-1). Predictions are on a continuous scale to remove interval 
and right censoring in the original titres. Data collected in a prospective field study in Turkey8 (see Fig. 3 of 
Knight-Jones et al. (2015) for details). The proportion of cattle with a particular titre is proportional to violin-
plot width. Box-plots within the violin-plot show median (white circle), inter-quartile range, minimum and 
maximum titres. Actual titres (“data”) below the detection threshold (1:32) were designated zero.
www.nature.com/scientificreports/
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Temporo-spatial variation in these factors will lead to clusters of high susceptibility. Mass vaccination, with a 
one-size-fits-all approach, is particularly vulnerable to this phenomenon and national scale models will usually 
lack the resolution and accuracy needed to identify these clusters.
Current FMD vaccination strategy and epidemiology. Adoption of ≥6PD50 vaccines and a two-dose 
primary course. Since this study was performed the vaccination policy in Turkey has changed and all cattle are 
now routinely vaccinated every six-months using ≥ 6PD50 vaccines with a two-dose primary course. This strategy 
has been accompanied by a dramatic reduction in reported outbreaks (about 1000 in 2013, 253 in 2014, and 263 
in 201528–31). However, in late 2015 there was a rapid and widespread epidemic32 following the introduction of a 
new serotype A strain, prompting the production of a better matched vaccine32,33.
Impact of the new control policy. Although a decline in incidence is consistent with programme impact, epidemic 
cycles are typical in the region34 and a simple assessment of national incidence cannot separate the impact of nat-
ural and vaccine immunity2. Long-term impact is uncertain as although improved vaccination should improve 
disease control, FMD virus is highly infectious, pockets of high susceptibility are unavoidable and further incur-
sions of new viruses, against which the vaccine may not protect, are likely due to cross-border animal movements.
Interpretation and limitations. Natural immunity. Immunity derived from natural infection was not 
considered as it could confound the assessment of vaccine protection. For example, having low levels of vaccine 
immunity increases the likelihood of infection and thus natural immunity. Therefore, areas where the control 
programme is ineffective could be masked.
Serotype Log10 SP titre Age [months]
October February
One-dose primary One-dose primary Two-dose primary
O
< 2
< 6 72% [69–73] 100% [100–100] 100% [100–100]
6 -< 18 45% [42–48] 76% [71–80] 51% [47–56]
18 -< 24 38% [33–44] 63% [55–71] 57% [48–67]
≥ 24 34% [28–42] 59% [48–69] 58% [48–69]
Total 42% [38–47] 68% [60–75] 60% [53–68]
0
< 6 62% [60–63] 100% [100–100] 100% [100–100]
6 -< 18 28% [26–31] 58% [52–65] 38% [33–43]
18 -< 24 22% [18–27] 44% [35–54] 38% [27–51]
≥ 24 19% [13–26] 39% [27–52] 38% [26–52]
Total 27% [23–31] 51% [43–59] 44% [35–54]
A
< 2
< 6 84% [83–86] 100% [100–100] 100% [100–100]
6 -< 18 64% [60–68] 81% [76–85] 63% [58–68]
18 -< 24 55% [48–63] 70% [60–78] 64% [53–74]
≥ 24 51% [41–61] 65% [52–76] 64% [52–75]
Total 59% [52–67] 73% [65–80] 68% [58–68]
0
< 6 73% [71–76] 100% [100–100] 100% [100–100]
6 -< 18 45% [41–49] 66% [60–71] 46% [41–51]
18 -< 24 35% [28–44] 51% [40–62] 44% [32–58]
≥ 24 30% [22–42] 45% [31–59] 44% [30–59]
Total 40% [34–47] 56% [47–66] 50% [40–61]
Asia-1
< 2
< 6 69% [67–71] 100% [100–100] 100% [100–100]
6 -< 18 42% [39–46] 74% [69–79] 53% [49–58]
18 -< 24 37% [32–44] 66% [58–74] 62% [52–71]
≥ 24 35% [29–43] 63% [52–73] 63% [52–73]
Total 41% [37–47] 70% [62–76] 64% [56–71]
0
< 6 60% [59–62] 100% [100–100] 100% [100–100]
6 -< 18 26% [24–29] 49% [43–56] 36% [31–41]
18 -< 24 22% [17–29] 41% [30–52] 38% [25–52]
≥ 24 20% [14–20] 39% [25–54] 39% [25–54]
Total 27% [23–33] 48% [38–58] 44% [33–54]
Table 3.  Median predicted proportion of the Turkish cattle population with an FMD Log10(Sp titre) of 
<2 and zero (below 1:32 dilution detection threshold), stratified by age [95% PI in brackets]. Estimates 
are made for one month after autumn vaccination (October) and one month before revaccination (February). 
Antibody levels in February were assessed with and without the routine use of a two-dose primary vaccination 
course (labelled “Two-dose”, and “One-dose” respectively). See table S1 for age distributions. 
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Overall population immunity, considering both vaccination and natural infection, can be assessed using 
representative sero-surveys35–37. However, this approach cannot distinguish whether immunity is derived from 
infection or vaccination, or both, and therefore, has limitations as a tool for evaluating a vaccination programme 
in endemic countries.
Including natural immunity in this modelling study would have been challenging. The epidemiology of FMD 
in Turkey is complex involving multiple viral strains and host species. Nationwide, group-specific estimates of 
virus exposure and immune response would be highly speculative in Anatolian Turkey, where many outbreaks 
are not reported and levels of under-reporting are uncertain and variable. In addition, estimates would have to 
consider the complexities of strain cross-protection, synergies between vaccine and viral antigen exposure and 
variable reactivity to the assays used to measure immunity. Most importantly for this study, this approach would 
not answer the question at hand, namely, what level of protection is provided by the vaccination strategy?
Maternal antibody. An additional simplification was the exclusion of maternally derived antibody. Looking at 
cattle with no prior infection, aged ≤ 7 months old, the maximum age when maternal protection was detected13, 
field studies of the evaluated vaccine8 found that from 23 unvaccinated calves 13%, 4% and 13% had an LPBE SP 
titre ≥ 1:102 for serotypes A, O and Asia-1 respectively, with a further 13%, 9% and 17% that were borderline. The 
extent to which this maternal immunity is derived from vaccination as opposed to natural infection is uncertain 
and, hence, was not incorporated in this study. Furthermore, the relationship between antibody levels and pro-
tection is not known for young calves and may differ to that seen for older cattle13. Nonetheless, vaccine derived 
protection in young cattle ≤ 7 months old will be greater than reported here.
Categorisation of age and number of vaccine doses. The model simplification, whereby adult cattle were evenly 
distributed between ages 2–5 years old, would have minimal impact on estimates of the proportion vaccinated or 
protected, as adult cattle with multiple vaccinations (≥ 3 doses) were treated as one group and few cattle are > 5 
years old13. As seen in other studies3, increased immunity from additional vaccination beyond three doses was not 
evident in the field data8, as long as cattle were recently vaccinated. However, data on the immunity of old cattle, 
vaccinated many times were limited8 and serological predictions for cattle < 24 months of age were more robust.
Death rates. Due to limitations in available data, death rates were not explicitly incorporated into the population 
model. However, variation in the rates at which older cattle are removed could affect seasonal variation in pop-
ulation immunity. To minimise this inaccuracy, as the census data used were collected in December, evaluations 
were also performed around this same period (Sept to March).
Relating antibody levels to protection. Although the exact interpretation of a serological protection thresh-
old is uncertain, it provides a useful benchmark measure of immunity. We assessed serological thresholds at 
which 70% of cattle are protected against generalised FMD lesions. However, these thresholds are derived after 
vaccine-homologous virus is injected into the tongue and protection against field challenge may be greater16, 
although this would also depend upon vaccine match38,39.
The low VN titres seen for Asia-1 vaccine-homologous virus were surprising and may reflect within-serotype 
strain differences in the relationship between serology and protection reported by some17,18,40 but not all studies15. 
Ultimately, predictions will be influenced by the antigenic match between the vaccine, the test and the challenge 
virus.
Strategies assessed. Assessment of more scenarios would have been useful, including the use of higher potency 
vaccines or yearly vaccination of adult cattle. Unfortunately, the required immune response data were not avail-
able. The ≥ 6PD50 vaccine subsequently used for mass vaccination in Turkey was not yet available and although 
two studies had reported the long-term antibody response after a single dose of ≥ 6PD50 vaccine7,27, using these 
data was thought too speculative. Different vaccines, even with the same potency, have been seen to provide 
different levels of immunity and protection41. Vaccines used for FMD eradication in Europe stimulated high and 
long-lasting antibody levels for years after cattle had been vaccinated several times3,42,43, however, this may not be 
the case for other vaccines.
Limitations and assumptions are further discussed in the Supplementary Discussion.
Findings in context. The findings of limited and variable vaccine protection are supported by other studies. 
FMD incidence is high in Anatolia with significant temporal, age and regional variation; surveys typically find 
about 15–20% of 6–18 month old cattle have serological evidence of prior infection30,44. Outbreak investigations 
have found variable vaccine coverage and although vaccination reduced the risk of FMD, incidence in vaccinated 
cattle was still high (35%)13.
In a process that took many decades, FMD has been controlled successfully using vaccination in South 
America45 and Europe46. However, when comparing this to FMD control in Anatolia there are many additional 
factors, besides vaccine protection, that must be considered. Levels of livestock mixing are high in Anatolia as 
most farms are smallholdings, densely concentrated within villages and dependent upon local and distant com-
munal grazing. Levels of livestock movements are high, particularly around the Kurban festival of slaughter which 
involves the transportation of a fifth of all cattle and sheep (personal communication A.N. Bulut). Application of 
biosecurity measures is limited in Anatolia and as most smallholders require access to communal grazing, enforc-
ing movement restrictions during outbreaks is challenging. Furthermore, extensive farmers in endemic regions 
may be less concerned about FMD outbreaks and less motivated to participate in control programmes47, this is 
compounded by the logistical challenges encountered when vaccinating many transhumant smallholders. Finally, 
livestock carrying new FMD viruses can enter Turkey from neighbouring endemic countries.
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The importance of using vaccines with independent quality assurance and proven potency cannot be empha-
sised enough. If vaccination is ineffective, veterinary services and farmers bear the burden of mass vaccination 
without reducing the burden of disease. Furthermore, loss of confidence in vaccination and reduced participation 
in future control programmes can have long lasting repercussions.
Conclusion
Low population immunity after FMD mass vaccination results from a) rapid antibody decay in vaccinated ani-
mals and b) a high proportion of animals that have not received a sufficient number of vaccine doses. Using 
higher potency vaccines and a two-dose primary course would result in longer lasting antibody titres being 
obtained at a younger age.
As most cattle have only been vaccinated ≤ 2 times, a more potent vaccine able to deliver greater immunity 
after only one or two doses would greatly increase population immunity. Immunity gaps will still exist as each 
round of mass vaccination is likely to exclude a quarter of all cattle. Prioritising repeated vaccination of young 
cattle, with high coverage, would help reduce this gap.
However, over-reliance on vaccination with limited movement controls or isolation of infected animals is not 
recommended as FMD virus is highly infectious and vaccine protection will still leave clusters of high suscepti-
bility7,13,48. Susceptibility is exacerbated if there is a high risk of exposure to new virus strains, against which the 
vaccine may not protect.
In many FMD-endemic countries livestock movement restrictions and biosecurity measures are difficult 
to implement. In this situation FMD control becomes heavily dependent upon vaccine protection. However, 
the extent to which FMD can be controlled by vaccination alone remains an unanswered question of global 
importance.
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